Bromoconduritol treatment delays intracellular transport of secretory glycoproteins in human hepatoma cell cultures
Previous studies in our laboratory have shown that specific glycan structures are required for the normal secretion of some glycoproteins. Bromoconduritol is known to inhibit the removal of the innermost glucose moiety from Glc3Man9(GlcNAc)2 precursor of N-linked glycoproteins. We have used this inhibitor to investigate the possible role of glycan structure in the intracellular transport of secretory glycoproteins of Hep G2 cultures. Cells were pretreated with 1 mM bromoconduritol for 1h, pulsed with [35S]-methionine for 10min and chased for varying intervals. Specific glycoproteins and albumin were immunoprecipitated from the cell lysate and medium. We found that bromoconduritol-treatment inhibited the secretion of α1-protease inhibitor, ceruloplasmin, α2-macroglobulin, transferrin, and α-fetoprotein. Apparently, the glucosylated high-mannose intermediate is not secreted, since glycoproteins in the medium are of complex form. We conclude that the removal of the innermost glucose residue from secretory glycoprotein represents an important regulatory step in the intracellular transport pathway. © 1989.
Yeo, Kiang Teck; Yeo, Tet Kin; and Olden, Kenneth, "Bromoconduritol treatment delays intracellular transport of secretory glycoproteins in human hepatoma cell cultures" (1989). Howard University Cancer Center Faculty Publications. 242.